On the question of blue sky stuff I have taken the following...

On the question of blue sky stuff I have taken the following from a Press Release posted by Awildana:
***********

“Gilead Announces Topline Data From Phase 3 STELLAR-3 Study ofSelonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis(NASH)

FOSTER CITY,Calif.--(BUSINESS WIRE)--Apr. 25, 2019-- Gilead Sciences,Inc. (Nasdaq: GILD) today announced that STELLAR-3 ………..did not meet the pre-specified week 48 primary endpoint of a≥ 1-stage histologic improvement in fibrosis without worsening of NASH.”………..

“While we had hoped for different outcomes from the STELLAR program, weremain focused and committed to developing highly effective treatments forpatients living with advanced fibrosis due to NASH. We are actively exploringthe STELLAR data and will work with external collaborators like PathAI andinsitro, to further our understanding of this complex disease and advance ourdevelopment programs. We thank the patients and their physicians whoparticipated in the STELLAR program for contributing to these efforts,” said JohnMcHutchison,AO, MD, Chief Scientific Officer and Head of Research and Development, GileadSciences. “We believe thateffective therapy for NASH will ultimately require a combination approach thattargets distinct pathways involved in the pathogenesis of this disease.”
***********
The yellow highlight is mine and is further confirmation of the opinion expressed by Prof Arun Sanyal that a treatment for NASH will require combination therapies. In this regard it is worth remembering that Prof Arun Sanyal who led the Immuron's Phase 2 NASH trial of IMM-124E (Travelan) was extremely excited about the ability of IMM-124E to lower LPS .

*********

"In parallel with today’s published results, study lead Principle Investigator Professor Arun Sanyal from the Virginia Commonwealth University in Richmond, USA said: “This is truly a proof of concept for this first-in-class drug candidate.

The IMM-124E drug candidate has been developed to target LPS in the gut and prevent it translocating into the portal circulation.

The study results clearly demonstrate a statistically significant reduction of serum LPS levels in the treatment groups when compared to placebo and provides us with a proof of concept that metabolic endotoxemia can indeed be decreased using this drug candidate (IMM-124E) which targets the endotoxin LPS.”

“We are encouraged that IMM-124E, a drug with an exceptional safety profile, can lower the LPS-associated inflammatory burden and improve liver enzymes. The potential clinical applications for this drug candidate are numerous and very exciting indeed,” said Professor Arun Sanyal."

********

When Travelan (IMM-124E) is approved by the FDA for prescription for travellers diarrhoea it will also be available for prescription for other purposes INCLUDING the lowering of LPS associated inflammatory burden for the purpose of improving liver enzymes as part of a combination approach to the targeting of distinct pathways involved in the pathogenesis of NASH.

If on top of the growth in Travelan sales and IMM-124E FDA approval there were also to be positive results in ASH and C.Diff the future value of this company is very difficult to contemplate.